Transgenic mice expressing inducible human p25

Details Transgenic mice expressing inducible human p25 Transgenic mice expressing inducible human p25

2007-07-31

2007-07-31

Crouch, Deborah (Department: 1632)

Multicellular living organisms and unmodified parts thereof and

Nonhuman animal

Transgenic nonhuman animal

C800S003000, C800S012000, C800S025000, C435S325000

Reexamination Certificate

active

10625986

ABSTRACT:
Disclosed are improved methods of treating individuals with Alzheimer's disease (AD) as well as methods to diagnose AD in an individual. Also included are compounds and methods of identifying compounds to treat AD. The present invention also discloses methods for decreasing the phosphorylation of amyloid precursor protein (APP), including inhibiting phosphorylation of amino acid residue tyrosine 668 of APP and for reducing cleavage of APP. The present invention further discloses transgenic (Tg), non-human animals and cells expressing a p25 transgene that are models of neurodegenerative diseases. Embodiments of the present invention are directed to methods wherein the Tg animals and Tg cells of the invention are used to screen for modulators of neurodegenerative disorders. The Tg animals and cells of the present invention are useful for elucidating the mechanisms of neurodegenerative disorders.

REFERENCES:
patent: 4736866 (1988-04-01), Leder et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 4870009 (1989-09-01), Evans et al.
patent: 4873191 (1989-10-01), Wagner et al.
patent: 4873316 (1989-10-01), Meade et al.
patent: 5223409 (1993-06-01), Ladner et al.
patent: 5225539 (1993-07-01), Winter
patent: 0 125 023 (1984-11-01), None
patent: 0 171 496 (1986-02-01), None
patent: 0 173 494 (1986-03-01), None
patent: 0 184 187 (1986-06-01), None
patent: 0 264 166 (1988-04-01), None
patent: WO 87/02671 (1986-03-01), None
patent: WO 86/01533 (1987-05-01), None
patent: WO 90/02809 (1990-03-01), None
patent: WO 91/17271 (1991-11-01), None
patent: WO 92/01047 (1992-01-01), None
patent: WO 92/09690 (1992-06-01), None
patent: WO 92/15679 (1992-09-01), None
patent: WO 92/18619 (1992-10-01), None
patent: WO 92/20791 (1992-11-01), None
patent: WO 93/01288 (1993-01-01), None
patent: WO 00/36093 (2000-06-01), None
patent: WO 01/57183 (2001-08-01), None
Ristevski et al, Molecular Biotechnology, 29: 153163, 2005.
Lucas et al, The EMBO Journal, 20(1 & 2): 27-39, 2001.
Cameron, Molecular Biotechnology, 7: 253-265, 1997.
Sigmund, Arterioscler Throm Vasc Biol 20: 1425-1429, 2000.
Mayford et al, Science, 24: 1678-1683, 1996.
Ahlijanian et al, PNAS, 97(6): 2910-1915, 2000.
Ahlijanian et al., “Hyperphosphorylated tau and neurofilament and cytoskeletal disruptions in mice overexpressing human p25, an activator of cdk5,”Proc. Natl. Acad. Sci., 97:2910-2915 (2000).
Bibb et al., “Phosphyorylation of DARPP-32 by Cdk5 modulates dopamine signaling in neurons,”Nature, 402:669-671 (1999).
Bibb et al., “Effects of chronic exposure to cocaine are regulated by the neuronal protein Cdk5,”Nature, 10:376-380 (2001).
Delalle et al., “Temporal and spatial patterns of expression of p35, a regulatory subunit of cyclin-dependent kinase 5, in the nervous system of the mouse,”J. Neurocytol., 26:283-296 (1997).
De Strooper and Annaert, “Proteolytic processing and cell biological functions of the amyloid precursor protein,”J. Cell Sci., 113:1857-1870 (2000).
Dhavan and Tsai, “A Decade of Cdk5,”Nat. Rev. Mol. Cell Biol., 2:749-759 (2001).
Fischer et al., “Cyclin Dependent Kinase 5 Is Required for Associative Learning,”J. Neurosci., 22(9):3700-3707 (2002).
Grynspan et al., “Active site-directed antibodies identify calpain II as an early-appearing and pervasive component of neurofibrillary pathology in Alzheimer's disease,”Brain Res., 763:145-158 (1997).
Gupta et al., “Life Is a Journey . . . ,”Nat. Rev. Genet., 3:342-357 (2002).
Hsiao et al., “Correlative Memory Devicits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice,”Science, 274:99-102 (1996).
Keshvara et al., “Cyclin-Dependent Kinase 5 Phosphorylates Disabled 1 Independently of Reelin Signaling,”J. Neurosci., 22:4869-4877 (2002).
Khachaturian, “Diagnosis of Alzheimer's Disease,”Arch. Neuro., 42:1097-1105 (1985).
Kusakawa et al., “Calpain-dependent Proteolytic Cleavage of the p35 Cyclin-dependent Kinase 5 Activator to p25,”J. Biol. Chem.275:17166 (1999).
Ledda et al., “Target-Derived GFRα1 as an Attractive Guidance Signal for Developing Sensory and Sympathetic Axons via Activation of Cdk5,”Neuron., 36:387-401 (2002).
Lewis et al., “Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein,”Nat. Genet., 25:402-405 (2000).
Lewis et al., “Enhanced Neurofibrillary Degeneration in Transgenic Mice Expressing Mutant Tau and APP,”Science, 293:1487-1491 (2001).
Li et al., “Regulation of NMDA receptors by cyclin-dependent kinase-5,”Proc. Natl. Acad. Sci. USA, 98(22):12742-12747 (2001).
Mattson, “Cellular Actions of β-Amyloid Precursor Protein and its Soluble and Fibrillogenic Derivatives,”Physiol. Rev., 77:1081-1132 (1997).
Mayford et al., “Control of Memory Formation through Regulated Expression of a CaMKII Transgene,”Science, 274:1678-1683 (1996).
Niethammer et al., “NUDEL Is a Novel Cdk5 Substrate that Associates with LISI and Cytoplasmic Dynein,”Neuron, 28:697-711 (2000).
Nikoloic et al., “The cdk5/p35 kinase is essential for neurite outgrowth during neuronal differentiation,”Genes Dev., 10:816-825 (1996).
Patrick et al., “Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodengeneration,”Nature, 402:615-622 (1999).
Price et al., “Amyloid beta amyloidosis in Alzheimer's disease,”Curr. Op. Neurol,. 8:268-274 (1995).
Ramelot et al., “Phosphorylation-induced Structural Changes in the Amyloid Precursor Protein Cytoplasmic Tall Detected by NMR,”J. Mol. Biol., 307:871-884 (2001).
Sasaki et al., “A LISI/NUDEL/Cytoplasmic Dynein Heavy Chain Complex in the Developing and Adult Nervous System,”Neuron, 28:681-696 (2000).
Sasaki et al., “Fyn and Cdk5 Mediate Semaphorin-3A Signaling, which Is Involved in REgulation of Dendrite Orientation in Cerebral Cortex,”Neuron, 35:907-920 (2002).
Selkoe, “Transplanting cell biology into therapeutic advances in Alzheimer's disease,”Nature, 399[Supp]:A23-A31 (1999).
Suri et al., “Catecholeminergic Cell Lines from the Brain and Adrenal Glands of Tyrosine Hydroxylase-SV40 T Antigen Transgenic Mice,”J. Neurosci., 13(3):1280-1291 (1993).
Tang et al., “An Isoform of the Neuronal Cyclin-dependent Kinase 5 (Cdk5) Activator,”J. Biol. Chem.270(45):26897-26903 (1995).
Taniguchi et al., “Calpain-mediated degradation of p35 to p25 in postmorten human and rat brains,”FEBS Lett.489:46-50 (2001).
Tomizawa et al., “Localization and Development Changes in the Neuron-Specific Cyclin-Dependent Kinase 5 Activator (p35nck5a) in the Rat Brain,”Neurosci., 74(2):519-529 (1996).
Tsai et al., “p35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5,”Nature371:419-423 (1994).
Tseng et al., “A survey of Cdk5 activator p35 and p25 levels in Alzheimer's disease brains,”FEBS Lett.523:58-62 (2002).
Yang and Hinds, “Increased Ezrin Expression and Activation by CDK5 Coincident with Acquisition of the Senescent Phenotype,”Mol. Cell, 11:1163-1176 (2003).
Yankner, “Mechanisms of Neuronal Degeneration in Alzheimer's Disease,”Neuron, 16:921-932 (1996).
Yoo and Lubec, “p25 protein in neurodegeneration,”Nature, 411:763-764 (2001).
Younkin, “Evidence that Aβ42 Is the Real Culprit in Alzheimer's Disease,”Ann. Neurol.37:287-288 (1995).
English abstract of WO 93/01288.
Cruz et al., “Aberrant Cdk5 activation by p25 triggers pathologcial events leading to neurodegeneration and neurofibrillary tangles,”Neuron., 40(3):471-483 (2003).
Wang et al., “Cdk5 activation induces hippocampal CAI cell death by directly phosphorylating NMDA receptors,”Nat. Neurosci., 6(10):1039-1047 (2003).
Zhang et al., “Cyclin-dependent kinase inhibitors atten

Affiliated with

Also associated with

Rating

Transgenic mice expressing inducible human p25 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Transgenic mice expressing inducible human p25, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Transgenic mice expressing inducible human p25 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3753588